CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Paricalcitoldrug
Likely dose
Paricalcitol 2 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01163162
NCT01163162Phase 4Completed
CompareCT.gov

The Effect of Paricalcitol on Creatinine Filtration, Secretion and Glomerular Filtration Rate

Indiana University·interventional·Posted Jul 15, 2010·Updated May 21, 2013

In Brief

A Phase 4 clinical trial evaluating Paricalcitol for Chronic Kidney Disease. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to study the effects of Paricalcitol (Zemplar) on kidney functioning. The investigators hypothesize that the increase in serum creatinine observed in recent paricalcitol trials is a function of reduced creatinine secretion and not an actual reduction in kidney function. 16 patients will have kidney function measured via iothalamate clearance at baseline, after 7 days of paricalcitol treatment and after 7 days of being washed off the paricalcitol.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsAbbott

Timeline

Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 15, 2010
Enrollment StartAug 1, 2010
Primary CompletionMar 1, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 16.0 years ago

Interventions

Paricalcitoldrug

2 mcg oral Paricalcitol once per day for 7 days